IL6 and COVID-19: Of note, in our model, IL-6, the expression of which can be modulated by montelukast, at concentrations comparable to those found in COVID-19 patients, significantly potentiated the effect of low-concentration adenosine diphosphate (ADP) or thromboxane A2, and accordingly, aspirin and the P2Y12 inhibitor AR-C69931MX prevented platelet activation induced by COVID-19 plasma (Canzano et al., 2021).